Sign in
Active, not recruitingPhase 2

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

Key facts

Who runs it
Vasomune Therapeutics, Inc.
Where
Chicago, Columbus, Denver, Detroit, Hyattsville, and Newport Beach, United StatesSee the 6 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
60 people enrolled
Started
20 Dec 2021
Ended
Sept 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • AV-001 Injection
  • AV-001 Placebo Injection
Record updated
29 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Able and willing to give signed informed consent
  • Patients hospitalized with a presumed diagnosis of pneumonia of < 48 hours duration requiring supplemental oxygen therapy. Eligible patients include those hospitalized for a separate non-infectious reason who subsequently develop a presumed pneumonia
  • Radiologic imaging (chest x-ray, CT scan, etc.) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation; Signs and symptoms:; At least 1 of the following signs:
  • respiratory rate > 30 breaths/min
  • fever (> 38.0ºC or > 100.4o F)
  • leukopenia (≤ 4,000 WBC/mm3 or leukocytosis (≥ 12,000 WBC/mm3)
  • adults ≥ 70 years of age; altered mental status with no other recognized cause; AND at least 1 of the following symptoms:
  • New onset of purulent sputum or change in character of sputum or increased respiratory secretions
  • New onset or worsening cough, or dyspnea, or tachypnea
  • Rales or bronchial breath sounds; Female patients of reproductive potential must be on an effective contraceptive method

Who cannot take part

  • Any concurrent serious medical condition or concomitant medication that would preclude participation in the study including but not limited to:; Septic shock as defined by systolic blood pressure (SBP) < 90 mmHg or diastolic blood pressure (DBP) of < 60 mmHg; Multiple organ failure; Are moribund irrespective of the provision of treatments; Any significant bleeding disorder or vasculitis; Any serious, nonhealing wound, peptic ulcer or bone fracture; Liver cirrhosis; History of a hypertensive crisis or hypertensive encephalopathy, or current, poorly controlled hypertension or hypotension; Severe renal insufficiency or end stage renal disease as determined by estimated glomerular filtration rate <30mL/min/1.73m2; ARDS risk factors of aspiration pneumonia, non-cardiac shock, trauma, blood transfusion or drug overdose
  • Symptomatic congestive heart failure or symptomatic or poorly controlled cardiac arrhythmia > class II as per New York Heart Association (NYHA) classification
  • History of autonomic disorders or uncontrolled hypotension
  • Hypersensitivity to drug products containing polyethylene glycol (PEG)
  • Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study
  • Pregnant and/or lactating women
  • Patients included in any other interventional trial
  • Use of endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at screening
  • Any thromboembolic event within the past 3 months

Where in United States

  • Northwestern University Medical CenterChicago, United States
  • The Ohio State UniversityColumbus, United States
  • Denver Health Medical CenterDenver, United States
  • Henry Ford Health SystemDetroit, United States
  • Medstar Health Research Institute, IncHyattsville, United States
  • Hoag Memorial Hospital PresbyterianNewport Beach, United States

About the trial

What the trial wants to find out

A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be recruited from up to 25 participating institutions/hospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).

The 2 groups in the trial

  • AV-001 Injection with standard of care (SOC).Existing treatment, for comparison

    A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC). Doses of AV-001 Injection will start with 12.5 μg/kg/day in cohort 1 and are anticipated to increase to 25 μg/kg/day in cohort 2, 56 μg/kg/day in cohort 3.

    Treatment: AV-001 Injection

  • AV-001 Placebo Injection with standard of care (SOC).Placebo, for comparison

    A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).

    Treatment: AV-001 Placebo Injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients Hospitalized With Pneumonia Due To COVID-19 or Other Respiratory Infections.
Record updated
29 September 2026